Abstract: Poster Presentations |


D. S. Pearlman, MD; W. Rees, MD; H. Huang; K. Schaefer, MSc; W. T. Andrews, MD, FACP*
Author and Funding Information

Sepracor Inc., Marlborough, MA

Chest. 2006;130(4_MeetingAbstracts):163S-d-164S. doi:10.1378/chest.130.4_MeetingAbstracts.163S-d
Text Size: A A A
Published online


PURPOSE: To compare the efficacy of levalbuterol HFA (LEV) 90 μg (2 actuations of 45 μg) with placebo (PBO, 2 actuations) administered via metered dose inhaler (MDI) in the prevention of exercise-induced bronchospasm (EIB) in patients with mild/moderate asthma.

METHODS: Patients ≥18 years participated in a randomized, double-blind, placebo-controlled, 2x2 crossover study. Patients had a ≥6-month history of EIB, ≥70% predicted FEV1 at baseline, and 20-50% decrease in FEV1 following standardized treadmill exercise challenge using single-blind PBO MDI. Eligible patients (n=15) self-administered LEV or PBO 30 minutes prior to exercise challenge. Treatment sequences were separated by a 3-7-day washout. Spirometry was performed predose, 20 minutes postdose/pre-exercise, and at 5, 10, 15, 30, and 60 minutes post-exercise. The primary endpoint was the maximum percent (%) decrease in FEV1 from baseline (postdose/pre-exercise). Area under curve for the % decrease from baseline FEV1 (FEV1 AUC[0-60 min]) and percentage of protected (≤20% decrease in post-exercise FEV1) patients were also assessed.

RESULTS: Compared with the maximum % decrease in FEV1 for PBO (adjusted mean ±SE: 22.5±2.8%), LEV (4.8±2.8%) demonstrated a significantly smaller (p<0.001) decrease in post-exercise FEV1. Significantly superior bronchoprotection was also observed for LEV (adjusted mean ±SE: 148.0±148.5%-min) in comparison with PBO (957.7±148.7%-min; p<0.001) for the % decrease in FEV1 AUC(0-60 min). A significantly higher percentage of LEV-treated patients (93.3%) were protected from EIB than PBO-treated patients (53.3%, p=0.0143). After LEV, 80.0% of patients had a <10% decrease in post-exercise FEV1 compared with 13.3% of patients after PBO. LEV was generally well tolerated.

CONCLUSION: In this trial, LEV HFA MDI 90 μg provided significant protection from EIB.

CLINICAL IMPLICATIONS: Levalbuterol HFA MDI may be beneficial for asthmatic patients with EIB. Support for this study provided by Sepracor Inc.

DISCLOSURE: W. Andrews, Employee Dr. Andrews, and Ms. Huang and Schaefer, are employees of Sepracor Inc.; Consultant fee, speaker bureau, advisory committee, etc. Drs. Pearlman and Rees are investigators for Sepracor Inc.; Other Support for this study provided by Sepracor Inc.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543